Skip to content
In English |
En español
Search
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 306
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
12/1/1998
1.
Phase II/III Randomized Study of Monoclonal Antibody HuM195 As Maintenance Therapy in Elderly Patients with Acute Myeloid Leukemia in Complete Remission Following Chemotherapy (Summary Last Modified 12/98)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Closed
60 and over
Pharmaceutical / Industry
PDL-3-251
MSKCC-93131, NCI-V94-0469
Last Modified:
6/1/2007
 
First Published:
10/1/1999
2.
Phase II/III Randomized Study of Leflunomide (SU101) With Mitoxantrone and Prednisone Versus Mitoxantrone and Prednisone Alone in Patients With Hormone Refractory Prostate Cancer (Summary Last Modified 01/2001)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Completed
18 and over
Pharmaceutical / Industry
SUGEN-SU101.035
SUGEN-990711, NCT00004071
Last Modified:
7/6/2007
3.
Phase II-III FAM (5-FU/ADR/MITO) vs V-FAM (FAM/VCR) vs Phase II Agent Chemotherapy for Advanced Gastric Adenocarcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Completed
no age specified
NCI
SWOG-7841
4.
Phase II/III Comparison of VBL/Single-Dose DHAD vs VBL/5-Day DHAD for Metastatic Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Closed
15 and over
MDA-MBDT-8085
5.
Phase III Chemotherapy with FAM-S(5-FU/ADR/MITO/SZC) vs Phase II Chemotherapy with Dihydroxyanthracenedione for Advanced Adenocarcinoma of the Pancreas
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Closed
under 70
NCI
SWOG-8040/43
SWOG-8043
6.
Phase II/III Chemotherapy with ADR vs DHAD vs ADC for Breast Cancer Not Previously Exposed to Intercalating Agents
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Completed
no age specified
NCI
SWOG-8203/04
SWOG-8204
Last Modified:
4/10/2008
7.
Phase III Randomized Study of Induction and Intensification Regimens for Childhood Acute Myeloid Leukemia: IDA vs DNR with ARA-C/VP-16 for Induction in All Patients and Intensification with High-Dose ARA-C/DHAD (HAM) Before vs After Consolidation in High-Risk Patients
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
under 17
GER-GPOH-AML-BFM-93
EU-93008
Last Modified:
6/1/1999
8.
Phase III Randomized Study of Mitoxantrone vs. Cyclophosphamide/Methotrexate/Fluorouracil (CMF) Chemotherapy for Good-Risk Metastatic Breast Cancer (Summary Last Modified 06/1999)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
35 to 80
GER-AIO-02/92
EU-93010
Last Modified:
5/3/2007
 
First Published:
1/1/1994
9.
Phase III Randomized Study of Mitoxantrone With or Without Docetaxel as First-Line Chemotherapy for Women With Poor Risk Metastatic Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
80 and under
Other
GER-AIO-01/92
EU-93011, NCT00002544
Last Modified:
5/4/2007
 
First Published:
1/1/1994
10.
Phase III Randomized Study of Intensive Therapy for Acute Myelogenous Leukemia (the AML 10 Protocol): IDA vs DHAD vs DNR with ARA-C/VP-16 for Induction and Intermediate-Dose ARA-C for Consolidation Followed by AlBMT vs AuBMT vs PBSC (Summary Last Modified 08/2000)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
15 to 60
EORTC-06931
NCT00002549
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute